ONCOLOGY PHARMA INC - ONPH STOCK NEWS

Oncology Pharma Inc. (OTC PINK:ONPH) held a meeting with its Board of Directors and Scientific Advisory Board, discussing advancements in their Co-Development plan aimed at expediting pharmaceutical drug commercialization. They highlighted the Connect2Med trials and the development of a dactinomycin nanoemulsion for pediatric cancer treatments, which shows promising initial results. The company is in early feasibility studies and anticipates further developments. However, risks related to financing, operational cash flows, and market acceptance were noted.

Oncology Pharma Inc. (OTC PINK:ONPH) provided a year-end update highlighting significant advancements in drug research and new licensing agreements. The company is focusing on developing a nanoemulsion of dactinomycin aimed at delivering effective cancer treatments with reduced side effects. It is also pursuing orphan drug designation for pediatric applications, targeting underserved markets. The firm has retained PCAOB auditors and is finalizing steps to potentially uplist to NASDAQ. Future growth is anticipated through strategic partnerships and innovative patient engagement platforms.

Oncology Pharma Inc. (OTC PINK:ONPH) is advancing its oncology research and development with a novel nanoemulsion of dactinomycin, aimed at improving safety and efficacy for cancer treatment. The company focuses on pediatrics and orphan drug designation for lower capital investment and high unmet needs. Initial studies show promising drug encapsulation and release profiles, with plans to submit Orphan Drug Designation requests in the USA and Europe. The investigational safety testing is projected to start in the first half of 2022, enhancing prospects for commercialization.

Oncology Pharma has announced progress in its collaboration with NanoSmart Pharmaceuticals to develop a new formulation of the cancer drug dactinomycin, targeting safer and more effective delivery mechanisms. The project aims to create a nanoparticle system that enhances drug accumulation at tumor sites. The company has licensed rights to the new formulation and established plans to seek FDA approval through an IND application. Initial phases of development are underway to assess the formulation's feasibility, potentially leading to advanced pre-clinical work.

Oncology Pharma Inc. (OTC PINK:ONPH) is advancing its Co-Development plan focused on new drug formulations for pediatric cancer treatment. The company is developing a dactinomycin nanoemulsion to enhance targeted delivery and minimize overall costs and time to market. A meeting is scheduled for November with the Board and advisors to discuss ongoing data, license agreements, and commercialization. However, the company faces potential risks including negative cash flow, funding needs, and uncertainties in market acceptance.

Oncology Pharma Inc. (OTC PINK:ONPH) has partnered with DBBMcKennon, a PCAOB Certified Public Accounting Firm, to audit its financials. This move is aimed at achieving compliance with SEC reporting standards and pursuing a listing on the NASDAQ Capital Markets. The management is focused on enhancing the company's growth potential. DBBMcKennon offers a range of services, including audit and consulting. The company, engaged in oncology therapeutics R&D, emphasizes its commitment to advancing cancer research technologies.

Oncology Pharma Inc. (OTC PINK:ONPH) announced significant updates regarding its business progress. The Company is finalizing its engagement with a PCAOB Audit firm to meet NASDAQ qualification requirements, expecting a selection soon. Additionally, Oncology Pharma is negotiating an extension to its licensing agreement with Ribera Solutions for the Connect2Med platform, which focuses on patient engagement in clinical trials. The Company aims to enhance its development in the oncology sector and will provide further updates as progress continues.

Oncology Pharma, Inc. (OTC PINK:ONPH) has successfully obtained and segregated funds necessary for the initial phase of developing a nanoemulsion of dactinomycin. An expert team in drug development is managing this phase, focusing on reducing costs and time for commercializing a new drug formulation. The next step will include assessing the nanoemulsion's safety in nonclinical studies before submitting an Investigational New Drug application to the FDA for human trials.

Oncology Pharma, Inc. (OTC PINK:ONPH) has outlined its strategy for a Co-Development deal focused on pediatric cancers, aiming to expedite drug commercialization and reduce costs. The project involves developing a dactinomycin nanoemulsion, which mitigates toxicity while improving delivery to tumor sites. Funding is secured for preclinical studies, with goals to submit an IND application to the FDA for human trials. The company emphasizes the need for improved therapies for rare pediatric cancers and plans to use its intellectual properties to meet this unmet need.